VolitionRx Advances Lung Cancer Management with New Findings
HENDERSON, Nev. — VolitionRx Limited (NYSE AMERICAN: VNRX), a pioneering epigenetics company, recently announced the successful presentation of two significant abstracts at the North America Conference on Lung Cancer (NACLC). This event showcased advancements in lung cancer care thanks to Volition's innovative Nu.Q® Cancer assays.
Impact of Nu.Q® Cancer Assays on Patient Outcomes
The findings presented at NACLC underscored the potential of Nu.Q® Cancer assays in enhancing management strategies for lung cancer patients. The studies revealed striking evidence of how these assays could serve as critical tools for clinicians when assessing and determining treatment pathways for their patients.
Understanding the Clinical Insights
Prominent medical professionals, including Professor Lea Payen, highlighted the importance of circulating H3K27Me3 levels in patients newly diagnosed with lung cancer. The research indicated that these levels not only increase with the stage of the disease but also serve as an independent prognostic biomarker, crucial for overall survival assessments.
"Our collaboration with the Volition team has fostered a robust body of evidence supporting the Nu.Q® Cancer assays’ role in personalized medicine," expressed Professor Payen. She also pointed out their recent acquisition of the first order of these assays, forging a path towards integrating them into routine clinical practice within hospital networks for comprehensive cancer management.
The Findings Behind the Assays
Another groundbreaking study, jointly led by Dr. Pei-Hsing Chen, revealed that preoperative H3K27Me3-nucleosome measurements using a simple blood test allow clinicians to identify Non-Small Cell Lung Cancer patients who are at a higher risk for recurrence. This insight enables better follow-up strategies and decisions regarding secondary treatments.
Dr. Chen stated, "Our findings demonstrate that high levels of H3K27Me3-nucleosomes correlate with poorer outcomes, while lower levels are more predictive of positive survival rates. This data is critical for determining systemic therapy strategies for high-risk patients. We are excited about the capabilities that the Nu.Q® technology offers to enhance treatment decisions throughout patient care.”
Importance of Precision Medicine in Lung Cancer
VolitionRx's Chief Medical Officer, Dr. Andrew Retter, elaborated on how the Nu.Q® Cancer assays represent a major leap forward in lung cancer management. He noted that these tools empower healthcare providers to make informed choices that can significantly impact patient outcomes.
Dr. Retter emphasized that through enriching clinical prognostication, clinicians can better identify the appropriate treatment pathways for each patient, ultimately contributing to improved survival rates and personalized care for lung cancer patients.
Future Directions and Commitments
As VolitionRx continues its dedication to advancing patient care, the company is committed to ensuring that their innovative testing methodologies can be fully utilized in clinical settings. This ambition aligns with their overarching goal: leveraging scientific breakthroughs to save lives.
About the North America Conference on Lung Cancer
The North America Conference on Lung Cancer is organized by the International Association for the Study of Lung Cancer. Established in 1974, the association boasts a membership of almost 9,000 lung cancer specialists spanning over 100 countries. This event is pivotal in disseminating new research findings and fostering collaboration within the lung cancer research community.
About VolitionRx Limited
VolitionRx Limited is a multi-national entity dedicated to the advancement of epigenetics. With a focus on saving lives, the company aims to improve outcomes associated with life-altering diseases through early detection and effective monitoring. Through its innovative blood tests, VolitionRx seeks to detect and monitor various diseases, including distinct cancer types and conditions related to NETosis, such as sepsis, thereby enhancing patient life quality. Their centers of research and development are located in Belgium, with additional innovation hubs in the United States and the United Kingdom.
Frequently Asked Questions
What is the significance of VolitionRx's presentations at NACLC?
The presentations highlighted the use of innovative diagnostic assays in lung cancer management, emphasizing their role as prognostic tools.
How do Nu.Q® Cancer assays affect treatment outcomes?
These assays provide critical clinical insights that help clinicians tailor treatment plans for better patient outcomes.
Who were the key contributors to the studies presented?
Prominent researchers like Professor Lea Payen and Dr. Pei-Hsing Chen played vital roles in these pivotal studies.
What specific findings were reported regarding H3K27Me3-nucleosomes?
The studies revealed that H3K27Me3-nucleosome levels correlate with cancer stage and prognosis, guiding treatment decisions.
What does the future hold for VolitionRx's technologies?
VolitionRx aims to integrate their innovative assays into clinical practice, enhancing personalized treatment and patient care.
